Related Experiment Videos
[Adjuvant systemic chemotherapy in colon cancer]
1Kirurgisk gastroenterologisk afdeling D, Amtssygehuset i Gentofte.
Ugeskrift for Laeger
|February 26, 1996
Summary
Adjuvant chemotherapy with fluorouracil and leucovorin significantly improves survival for high-risk colon cancer patients after surgery. This treatment is recommended, and further trials are needed to optimize regimens.
Area of Science:
- Oncology
- Surgical Oncology
- Gastrointestinal Oncology
Background:
- Colon cancer prognosis is often poor, with high rates of metastatic disease after resection.
- Adjuvant chemotherapy has emerged as a critical component of treatment for high-risk patients.
Purpose of the Study:
- To review the evidence supporting adjuvant chemotherapy for colon cancer.
- To establish a consensus on the use of adjuvant chemotherapy in Denmark.
Main Methods:
- Review of randomized controlled trials on adjuvant therapy for colon cancer.
- Analysis of disease-free survival and overall survival data.
- Assessment of treatment-related toxicity.
Main Results:
- Adjuvant therapy with fluorouracil, levamisole, or leucovorin significantly increases disease-free and overall survival.
- Treatment toxicity is acceptable, though it increases with age.
- Adjuvant chemotherapy is recommended for high-risk patients, particularly those with Dukes' C colon carcinoma.
Conclusions:
- Adjuvant chemotherapy, including 5-fluorouracil and leucovorin, is recommended for patients with resected Dukes' C colon carcinoma.
- While "no-treatment" controls are no longer ethical, further randomized trials are necessary to determine optimal adjuvant chemotherapy regimens.